Astellas Pharma and YASKAWA Electric have agreed to form a joint venture. This venture aims to improve cell therapy manufacturing. The initiative targets major industry issues. These include the complexity, accuracy, and scalability of cell therapy production. The joint venture will use Astellas’ research and development skills. It will also use YASKAWA’s automation strengths. This includes its dual-arm robot, “Maholo,” created by the Robotic Biology Institute.
Integrating robotics into cell therapy manufacturing aims to boost precision, reproducibility, and efficiency. This collaboration also helps lessen the need for a specialized workforce. The venture will also provide startups and schools access to the platform. This will help boost innovation in the industry.
こちらもお読みください： 下剤不要のバーチャル内視鏡システムを開発するボストン・メディカル・サイエンスが$930万ドルを追加調達
This trend matches what we see in the pharmaceutical and biotech fields. They are moving towards automation in advanced therapies. The joint venture is ready to advance cell therapies and boost robotics in life sciences. Regulatory approvals are still pending.
